ATARA BIOTHERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-03-07
- ATARA BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00.
- ATARA BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $13.43M.
- ATARA BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $312.00K, a 99.39% decline from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $50.78M, a 278.19% increase from fiscal 2021.
- ATARA BIOTHERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $13.43M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-07 | |||
| 2023-12-31 | $312.00K 10-K · filed 2025-03-07 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $0.00 derived: sum of 2 quarters · filed 2024-03-28 | $50.78M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $50.78M 10-Q · filed 2022-11-08 | ||
| 2022-06-30 | $50.78M 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $13.43M derived: sum of 2 quarters · filed 2023-02-08 | $13.43M 10-K · filed 2023-02-08 | |
| 2021-09-30 | $13.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $13.43M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $0.00 10-K · filed 2023-02-08 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $838.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $838.00K 10-Q · filed 2019-11-07 | ||
| 2019-06-30 | $838.00K 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |